1-3 of 3
Raquel Merino Herranz
Close
Sort by
Journal Articles

Study Design and Initial Baseline Characteristics in Solace-Kids: Crizanlizumab in Pediatric Patients with Sickle Cell Disease

Matthew M. Heeney, MD, David C. Rees, MD, Mariane de Montalembert, MD PhD, Isaac Odame, MD, R. Clark Brown, MD PhD, Yasser Wali, MD, Thu Thuy Nguyen, Du Lam, MD, Raquel Merino Herranz, Julie Kanter, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–24.
https://doi.org/10.1182/blood-2020-137081
Published: 2020
Journal Articles

New Film-Coated Tablet Formulation of Deferasirox Is Well Tolerated in Patients with Thalassemia or MDS: Results of the Randomized, Phase II E.C.L.I.P.S.E. Study

Ali T. Taher, MD PhD, Raffaella Origa, Silverio Perrotta, Alexandra Kouraklis, Giovan Battista Ruffo, Antonis Kattamis, MD, Ai-Sim Goh, Annelore Cortoos, Vicky Huang, Marine Weill, Raquel Merino Herranz, John B. Porter, BA MB BChir MRCP(Path) FRCP(Path) MD
Journal: Blood
Blood (2016) 128 (22): 1285.
https://doi.org/10.1182/blood.V128.22.1285.1285
Published: 2016
Journal Articles

Improved Patient-Reported Outcomes with a Film-Coated Versus Dispersible Tablet Formulation of Deferasirox: Results from the Randomized, Phase II E.C.L.I.P.S.E. Study

Ali T. Taher, MD PhD, Raffaella Origa, Silverio Perrotta, Alexandra Kouraklis, Giovan Battista Ruffo, Antonis Kattamis, MD, Ai-Sim Goh, Annelore Cortoos, Vicky Huang, Marine Weill, Raquel Merino Herranz, John B. Porter, BA MB BChir MRCP(Path) FRCP(Path) MD
Journal: Blood
Blood (2016) 128 (22): 850.
https://doi.org/10.1182/blood.V128.22.850.850
Published: 2016